Exclusive Journals Coverage

Exclusive Journals Coverage articles provide quick insight and additional author perspectives on select studies recently published in Journal of Clinical Oncology and Journal of Oncology Practice.

Dec 22, 2014
The study found that caregivers whose children or charges experienced five or more unexpected hospitalizations during the first to fifth year after diagnosis, and caregivers who had quit or changed jobs within that same time period reported a significantly higher financial burden . . .
Dec 15, 2014
“The takeaway message from our study is that the colorectal cancer survivors who both watched less TV and did more exercise had the lowest mortality compared to those who watched more TV and did less exercise.”
Dec 08, 2014
A phase II, multicenter study published in the Journal of Clinical Oncology (JCO) found that patients with pancreatic neuroendocrine tumors who were treated with combined mTOR inhibitor temsirolimus and VEGF-A monoclonal antibody bevacizumab showed a response rate (RR) of 41%, meaning that tumors shrank in 23 out of the 56...
Nov 24, 2014
Children who receive stem cell transplantation (SCT) are at risk for long-term delays in cognitive functioning—but only if they are younger than three years of age before the transplant and if they receive total body irradiation (TBI) before the transplant . . .
Nov 17, 2014
“Our study suggests that a telephone-based peer support program that involves multiple contacts between the peer and the woman being supported is effective in reducing women's cancer-related distress and unmet information needs—at least in the short term,” 
Nov 10, 2014
A new study in the Journal of Clinical Oncology finds that women who received endocrine therapy following initial breast cancer treatments . . . were significantly more likely to report greater problems in a specific cognitive domain: word and phrase retrieval . . .
Nov 03, 2014
According to first author, Bradley N. Reames, MD, MS, the study, “Geographic Variation in Use of Laparoscopic Colectomy for Colon Cancer,” is “the first study to look at geographical variability as a factor in determining whether patients have access to minimally invasive surgery.” 
Oct 27, 2014
A new study asks . . . are there additional biomarkers, independent of HER2, that can help to identify who might benefit from anti-HER2 monoclonal antibodies, specifically the combination of pertuzumab plus trastuzumab?
Oct 20, 2014
“We can now conclude for science in general, that adding trastuzumab to chemotherapy for patients with HER2-positive breast cancers significantly improves disease-free progression and overall survival, even in the long term,” said study first author, Edith A. Perez, MD . . .
Oct 06, 2014
The study found that, compared to survivors of CRC who were of a normal weight before diagnosis, survivors of CRC who were overweight before diagnosis had a 39% greater risk of being diagnosed with a second obesity-related cancer, whereas those who were obese had a 47% greater risk.

Pages